News & Events

BD Medical-Pharmaceutical Systems, a unit of BD (Becton, Dickinson and Co), congratulated Wyeth Pharmaceuticals today on their recent market launch of a new prefilled delivery system for Prevnar®, a recommended infant vaccine, which will be delivered to patients using the BD Hypak SCF™ prefill system. BD Medical’s partnership with Wyeth helps provide a more convenient delivery system for Prevnar®.

“This is great news for Wyeth and for families and we offer sincere congratulations on this recent approval,” said Linda Tharby, Vice President and General Manager US, BD Medical – Pharmaceutical Systems. “The availability of Prevnar® in combination with the BD Hypak SCF™ system will make delivery of this vaccine for infants more convenient.”

BD Hypak SCF™ is the preferred medication delivery system by pharmaceutical companies for vaccines and therapeutic drugs. Prefilled BD Hypak SCF™ minimizes medication errors, ensures optimal aseptic drug delivery, and, as a result, contributes to cost reduction related to care and drug deliveries. BD’s prefilled injectables require less “over fill” than standard medication vials, resulting in the ability to vaccinate a larger number of patients with the same amount of vaccine. Additionally, this single-use system eliminates the need for preservatives to maintain product sterility.

Prevnar® helps to protect infants and toddlers from certain pneumococcal bacteria that can cause life-threatening meningitis and blood infections. Prevnar® is approved for use in infants as part of their routine vaccination schedule. Prevnar® was approved by the FDA in February 2000, but has been available only in single-dose vials. Prevnar® is now available in prefilled syringes, the exclusive delivery system.

About BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. For more information, please visit www.bd.com.